01:01 , Dec 7, 2018 |  BC Week In Review  |  Financial News

Hillhouse backs Elpiscience's $35M round

Elpiscience Biopharma Ltd. (Shanghai, China) raised $35 million in a series A+ round led by Hillhouse Capital Management. Existing investor Lilly Asia Ventures and CDH Investments also participated in the round. Elpiscience is stocking its...
21:12 , Dec 4, 2018 |  BC Extra  |  Financial News

Hillhouse backs Elpiscience's $35M round

Elpiscience Biopharma Ltd. (Shanghai, China) raised $35 million in a series A+ round led by Hillhouse Capital Management. Existing investor Lilly Asia Ventures and CDH Investments also participated in the round. Elpiscience is stocking its...
19:35 , Aug 31, 2018 |  BC Week In Review  |  Financial News

China GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
18:44 , Aug 31, 2018 |  BC Week In Review  |  Financial News

China Biologic spurns acquisition proposal, seeks $590M raise

Plasma products company China Biologic Products Holdings Inc. (NASDAQ:CBPO) said it turned down an acquisition proposal made on Aug. 17, and said it is raising $590 million in a private placement. The Aug. 17 proposal...
20:15 , Aug 24, 2018 |  BC Extra  |  Company News

China Biologic spurns acquisition proposal, seeks $590M raise

Plasma products company China Biologic Products Holdings Inc. (NASDAQ:CBPO) said it turned down an acquisition proposal made last week, and said it is raising $590 million in a private placement. The Aug. 17 proposal to...
22:12 , Aug 22, 2018 |  BC Extra  |  Financial News

China's GL Capital claims 5% stake in U.K.'s Oxford BioDynamics

Epigenetic biomarker company Oxford BioDynamics plc (LSE:OBD) partnered with GL Capital Group to address demand for healthcare and personalized medicine in China. The Greater China healthcare-focused firm will act as the U.K.-based biotech's lead mainland...
21:07 , Aug 20, 2018 |  BC Extra  |  Company News

Consortium including Gao, GL Capital bid to take China Biologic private

A consortium comprising former executive David Gao, GL Capital Group, Bank of China Group Investment Ltd. and CDH Investments proposed on Friday to take plasma products company China Biologic Products Holdings Inc. (NASDAQ:CBPO) private for...
19:25 , Jan 26, 2018 |  BC Week In Review  |  Financial News

Harbour BioMed raises undisclosed series A+

Harbour BioMed (Shanghai, China) raised an undisclosed series A+ round on Jan. 22 led by new investor CDH Investments. Existing investor Advantech Capital participated. This month, Harbour granted BeiGene Ltd. (NASDAQ:BGNE) and ImmunoChina Pharmaceuticals Co....
00:08 , Jan 23, 2018 |  BC Extra  |  Financial News

CDH leads Harbour BioMed round

Harbour BioMed (Shanghai, China) raised an undisclosed series A+ round led by new investor CDH Investments. Existing investor Advantech Capital participated. This month, Harbour granted BeiGene Ltd. (NASDAQ:BGNE) and ImmunoChina Pharmaceuticals Co. Ltd. rights to...
20:21 , Jun 9, 2017 |  BC Week In Review  |  Company News

SciClone going private in $605M deal

SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) said it will be acquired by an investor syndicate led by GL Capital Management for $11.18 per share in cash, or about $605 million. Other investors include Bank of China Group...